ReviewCardiovascular drugs and therapy2022
The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review.
Review in Cardiovascular drugs and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 48 citations in OpenAlex.
- Cardiovascular Risk Stratification and Surveillance in Cardio-Oncology: Mechanistic Foundations and Future Directions.Biomedicines · 2026Review
- Disproportionality analysis of drug-induced myocarditis: Insights from the Food and Drug Administration Adverse Event Reporting System database.The Journal of international medical research · 2026Article
- Persistent Ischemia-Like Electrocardiographic Changes in a Young Breast Cancer Patient on Trastuzumab: A Case Report.Cancer reports (Hoboken, N.J.) · 2026Article
- Osthole attenuates trastuzumab-induced cardiotoxicity in mice by enhancing autophagy via regulating the p38MAPK/mTOR signaling pathway.Journal of traditional and complementary medicine · 2026Article
- Heartbreakers and healers: RNA rebels in cardio-oncology.Seminars in cancer biology · 2026Review
- Signaling pathways and potential therapeutic agents in trastuzumab-induced cardiotoxicity.Apoptosis : an international journal on programmed cell death · 2026Review
- Immunotherapy-associated Cardiotoxicity: a Comprehensive Review of Checkpoint inhibitors, monoclonal, cellular, and cytokine-based Treatments.Current treatment options in oncology · 2025Review
- A serum biomarker panel for early detection of treatment-related cardiotoxicity in early HER2-positive breast cancer patients.Annals of medicine and surgery (2012) · 2025Article
- The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts.Protein & cell · 2025Review
- Cardio-Oncology and Multi-Imaging Modalities.Journal of clinical medicine · 2025Review
- Comprehensive review of non-invasive-treatment-related cardiovascular toxicity in breast cancer.iScience · 2025Review
- Article
- The mitigatory capabilities of exercise on breast cancer chemotherapy-induced cardiotoxicity.Frontiers in cell and developmental biology · 2025Review
- Machine learning modeling of cancer treatment-related cardiac events in breast cancer: utilizing dosiomics and radiomics.Frontiers in oncology · 2025Article
- A Case of Ventricular Arrhythmia in a Patient With HER2-Positive Gastric Cancer Receiving Trastuzumab.Case reports in gastrointestinal medicine · 2025Article
- Design, synthesis, and anticancer assessment of structural analogues of (RSC medicinal chemistry · 2024Article
- Endothelin-based markers for endothelial dysfunction in chemotherapy-induced cardiotoxicity.Journal of molecular and cellular cardiology plus · 2023Review
- Acetylcholinesterase inhibition protects against trastuzumab-induced cardiotoxicity through reducing multiple programmed cell death pathways.Molecular medicine (Cambridge, Mass.) · 2023Article
- Review
- Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer.Irish journal of medical science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
aimIn recent decades, there has been a revolutionary decrease in cancer-related mortality and an increase in survival due to the introduction of novel targeted drugs. Nevertheless, drugs targeting human epidermal growth factor receptor 2 (HER-2), angiogenesis, and other tyrosine kinases also come with unexpected cardiac side effects, including heart failure, hypertension, arterial thrombosis, and arrhythmias, and have mechanisms that are unlike those of classic chemotherapeutic agents. In addition, it is challenging to address some problems, as the existing guidelines need to be more specific, and further large-scale clinical trials and experimental studies are required to confirm the benefit of administering cardioprotective agents to patients treated with targeted therapies. Therefore, an improved understanding of cardiotoxicity becomes increasingly important to minimize the pernicious effects and maximize the beneficial effects of targeted agents.
methods"Cardiotoxicity", "targeted drugs", "HER2", "trastuzumab", "angiogenesis inhibitor", "VEGF inhibitor" and "tyrosine kinase inhibitors" are used as keywords for article searches.
resultsIn this article, we report several targeted therapies that induce cardiotoxicity and update knowledge of the clinical evidence, molecular mechanisms, and management measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.